Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Income from Continuing Operations data on record, last reported at 2028223.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 21.23% year-over-year to 2028223.0; the TTM value through Dec 2025 reached 7664363.0, up 3.06%, while the annual FY2025 figure was 8162133.0, 6.34% down from the prior year.
  • Income from Continuing Operations reached 2028223.0 in Q4 2025 per INM's latest filing, down from 1726899.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 336591.0 in Q2 2023 and bottomed at 7870023.0 in Q2 2022.
  • Average Income from Continuing Operations over 5 years is 2562619.11, with a median of 2063155.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 95.72% in 2023, then crashed 473.57% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 4282814.0 in 2021, then surged by 51.01% to 2098087.0 in 2022, then rose by 29.55% to 1478185.0 in 2023, then plummeted by 74.2% to 2575024.0 in 2024, then rose by 21.23% to 2028223.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 2028223.0 in Q4 2025, 1726899.0 in Q3 2025, and 1788311.0 in Q2 2025.